重组人生长激素对脓毒症大鼠的保护作用及机制研究
|
摘要
目的：构建脓毒症大鼠实验模型,观察重组人生长激素(rhGH)对脓毒症大鼠的保护作用。
方法：SD大鼠75只,随机分为3组(每组25只)：A组为对照组,仅予以开腹游离盲肠,B组为脓毒症组,开腹游离盲肠并行盲肠结扎穿孔术制造脓毒症模型,C组为rhGH治疗组,行盲肠结扎穿孔模型的同时予以皮下注射rhGH1.0U/kg一次,0h、2h、8h、12h、24h后观察大鼠血清谷丙转氨酶(ALT)活性、TNF-α水平和死亡率,24h后取心脏血行血培养。比较不同时间点ALT活性、TNF-α表达、死亡率和24h血培养结果。
结果：A组未见大鼠死亡,B组24h存活率48%(12／25)、C组24h存活率76%(19／25)。与A组相比,B、C组大鼠血清中ALT、TNF-α表达、血培养阳性率明显增加(P<0.05),而与B组相比,C组大鼠血清中ALT、TNF-α表达、血培养阳性率明显降低(P<0.05)。
结论：1、成功构建盲肠结扎穿孔的大鼠实验性脓毒症模型。
2、重组人生长激素对盲肠结扎穿孔诱导的大鼠脓毒症具有明显的保护作用。
目的：观察重组人生长激素对盲肠结扎穿孔诱导的脓毒症大鼠肝脏的影响,并初步探讨其作用机制。
方法：实验动物分组、脓毒症模型的构建及实验动物给药同第一部分,real-time PCR测定肝组织中TNF-αmRNA和HMGB1 mRNA的表达,Western blot测定肝组织中HMGB1和活化Caspase-3的蛋白表达,免疫组化测定肝组织中NF-κB的表达,原位凋亡检测TUNEL法检测肝细胞的凋亡情况。
结果：与A组相比,B、C组大鼠肝组织中TNF-αmRNA、HMGB1 mRNA、HMGB1和活化Caspase-3表达增加,NF-κB核移位及肝细胞凋亡增加(P<0.05)。与B组相比,rhGH可以明显降低C组大鼠肝组织中TNF-αmRNA、HMGB1 mRNA、HMGB1和活化Caspase-3的表达,减少NF-κB核移位及肝细胞凋亡(P<0.05)。
结论：rhGH通过抑制大鼠肝组织NF-κB活化,下调TNF-α、HMGB1表达,降低活化Caspase-3蛋白表达及肝细胞的凋亡,对肝细胞产生一定保护作用。
Objective:To investigate the protective effect of recombinant human growth hormone(rhGH) on sepsis in rats.
Methods:seventy-five SD rars were randomly divided into 3 groups, sham operation group(group A), sepsis group(group B) and rhGH group(group C). Cecal ligation and puncture operation were done in sepsis and rhGH group. In addition, rhGH(1u/kg) was injected subcutaneously at the same time point operation performed in group C. Death rate of each group at 24 hours after operation was caculated and survived rats were killed in order to get blood and liver samples. Activity of ALT was tested and level of TNF-a was detected by ELISA. Bacteria translocation were detected by blood culture.
Results:The survival rate in 24 hours was 100% in group A,48% in group B and 76% in group C. The activity of ALT, lever of TNF-a and positive rate of blood culture in group B and C were significantly higher than that in group A(P<0.05). The activity of ALT, lever of TNF-a and positive rate of blood culture in group C were significantly lower than that in group B(P<0.05).
Conclusion:The Cecal ligation and puncture operation induced sepsis in rats were established successfully. Recombinant human growth hormone had an obviously protective effect on Cecal ligation and puncture operation induced sepsis rats.
Objective:To investigate the mechanism of recombinant human growth hormone on sepsis in rats liver.
Methods:seventy-five SD rars were randomly divided into 3 groups, sham operation group(group A), sepsis group(group B) and rhGH group(group C). Cecal ligation and puncture operation were done in sepsis and rhGH group. In addition, rhGH(1u/kg) was injected subcutaneously at the same time point operation performed in group C. Survived rats were killed in order to get liver samples at 24 hours after operation. The expression of TNF-a mRNA and HMGB1 mRNA were tested by real-time PCR. The expression of HMGB1 and active Caspase-3 were detected by western blot. Nucleal positive rate of NF-KBp65 protein in liver tissue was determined by immunohistochemical staining. Apoptosis of liver cell was measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL).
Results:The expression of TNF-a mRNA, HMGB1 and active Caspase-3 in group B and C were significantly higher than that in group A(P<0.05). Nucleal positive rate of NF-κBp65 protein in liver tissue and apoptosis of liver cell in group B and C were markedly higher than that in group A(P<0.05). The expression of TNF-a mRNA, HMGB1 and active Caspase-3 in group C were greatly lower than that in group B(P<0.05). Nucleal positive rate of NF-KBp65 protein in liver tissue and apoptosis of liver cell in group C were prominently lower than that in group B(P<0.05).
Conclusion:Recombinant human growth hormone can protect the liver by decreasing the apoptosis of liver cell in sepsis, inhibiting the production and release of inflammatory factors such as TNF-αand HMGB1, inhibiting activation of NF-κB in liver.
方法：SD大鼠75只,随机分为3组(每组25只)：A组为对照组,仅予以开腹游离盲肠,B组为脓毒症组,开腹游离盲肠并行盲肠结扎穿孔术制造脓毒症模型,C组为rhGH治疗组,行盲肠结扎穿孔模型的同时予以皮下注射rhGH1.0U/kg一次,0h、2h、8h、12h、24h后观察大鼠血清谷丙转氨酶(ALT)活性、TNF-α水平和死亡率,24h后取心脏血行血培养。比较不同时间点ALT活性、TNF-α表达、死亡率和24h血培养结果。
结果：A组未见大鼠死亡,B组24h存活率48%(12／25)、C组24h存活率76%(19／25)。与A组相比,B、C组大鼠血清中ALT、TNF-α表达、血培养阳性率明显增加(P<0.05),而与B组相比,C组大鼠血清中ALT、TNF-α表达、血培养阳性率明显降低(P<0.05)。
结论：1、成功构建盲肠结扎穿孔的大鼠实验性脓毒症模型。
2、重组人生长激素对盲肠结扎穿孔诱导的大鼠脓毒症具有明显的保护作用。
目的：观察重组人生长激素对盲肠结扎穿孔诱导的脓毒症大鼠肝脏的影响,并初步探讨其作用机制。
方法：实验动物分组、脓毒症模型的构建及实验动物给药同第一部分,real-time PCR测定肝组织中TNF-αmRNA和HMGB1 mRNA的表达,Western blot测定肝组织中HMGB1和活化Caspase-3的蛋白表达,免疫组化测定肝组织中NF-κB的表达,原位凋亡检测TUNEL法检测肝细胞的凋亡情况。
结果：与A组相比,B、C组大鼠肝组织中TNF-αmRNA、HMGB1 mRNA、HMGB1和活化Caspase-3表达增加,NF-κB核移位及肝细胞凋亡增加(P<0.05)。与B组相比,rhGH可以明显降低C组大鼠肝组织中TNF-αmRNA、HMGB1 mRNA、HMGB1和活化Caspase-3的表达,减少NF-κB核移位及肝细胞凋亡(P<0.05)。
结论：rhGH通过抑制大鼠肝组织NF-κB活化,下调TNF-α、HMGB1表达,降低活化Caspase-3蛋白表达及肝细胞的凋亡,对肝细胞产生一定保护作用。
Objective:To investigate the protective effect of recombinant human growth hormone(rhGH) on sepsis in rats.
Methods:seventy-five SD rars were randomly divided into 3 groups, sham operation group(group A), sepsis group(group B) and rhGH group(group C). Cecal ligation and puncture operation were done in sepsis and rhGH group. In addition, rhGH(1u/kg) was injected subcutaneously at the same time point operation performed in group C. Death rate of each group at 24 hours after operation was caculated and survived rats were killed in order to get blood and liver samples. Activity of ALT was tested and level of TNF-a was detected by ELISA. Bacteria translocation were detected by blood culture.
Results:The survival rate in 24 hours was 100% in group A,48% in group B and 76% in group C. The activity of ALT, lever of TNF-a and positive rate of blood culture in group B and C were significantly higher than that in group A(P<0.05). The activity of ALT, lever of TNF-a and positive rate of blood culture in group C were significantly lower than that in group B(P<0.05).
Conclusion:The Cecal ligation and puncture operation induced sepsis in rats were established successfully. Recombinant human growth hormone had an obviously protective effect on Cecal ligation and puncture operation induced sepsis rats.
Objective:To investigate the mechanism of recombinant human growth hormone on sepsis in rats liver.
Methods:seventy-five SD rars were randomly divided into 3 groups, sham operation group(group A), sepsis group(group B) and rhGH group(group C). Cecal ligation and puncture operation were done in sepsis and rhGH group. In addition, rhGH(1u/kg) was injected subcutaneously at the same time point operation performed in group C. Survived rats were killed in order to get liver samples at 24 hours after operation. The expression of TNF-a mRNA and HMGB1 mRNA were tested by real-time PCR. The expression of HMGB1 and active Caspase-3 were detected by western blot. Nucleal positive rate of NF-KBp65 protein in liver tissue was determined by immunohistochemical staining. Apoptosis of liver cell was measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL).
Results:The expression of TNF-a mRNA, HMGB1 and active Caspase-3 in group B and C were significantly higher than that in group A(P<0.05). Nucleal positive rate of NF-κBp65 protein in liver tissue and apoptosis of liver cell in group B and C were markedly higher than that in group A(P<0.05). The expression of TNF-a mRNA, HMGB1 and active Caspase-3 in group C were greatly lower than that in group B(P<0.05). Nucleal positive rate of NF-KBp65 protein in liver tissue and apoptosis of liver cell in group C were prominently lower than that in group B(P<0.05).
Conclusion:Recombinant human growth hormone can protect the liver by decreasing the apoptosis of liver cell in sepsis, inhibiting the production and release of inflammatory factors such as TNF-αand HMGB1, inhibiting activation of NF-κB in liver.
引文
[1]Tsoyi K, Lee TY, Lee YS, et al. Heme-oxygenase-1 induction and carbon monoxide-releasing molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box 1 release in vitro and improve survival of mice in LPS-and cecal ligation and puncture-induced sepsis model in vivo. Mol Pharmacol,2009,76:173-82.
[2]Schlichting D, McCollam JS. Recognizing and managing severe sepsis:a common and deadly threat. South Med J,2007,100:594-600.
[3]Toussaint S, Gerlach H. Activated protein C for sepsis. N Engl J Med, 2009,361:2646-52.
[4]Kim JH, Kim SJ, Lee IS, et al. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol, 2009,182:2458-66.
[5]Koskinas J, Gomatos IP, Tiniakos DG, et al. Liver histology in ICU patients dying from sepsis:a clinico-pathological study. World J Gastroenterol, 2008,14:1389-93.
[6]Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med,2004,255:332-43.
[7]Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med,2003,9:37-45.
[8]Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol,2005,78:1-8.
[9]Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature,2002,418:191-5.
[10]Sha Y, Zmijewski J, Xu Z, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol,2008,180:2531-7.
[11]Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1):nuclear weapon in the immune arsenal. Nat Rev Immunol,2005,5:331-42.
[12]Stern D, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev,2002,54:1615-25.
[13]Mishra PR, Jain NK. Surface modified methotrexate loaded erythrocytes for enhanced macrophage uptake. J Drug Target,2000,8:217-24.
[14]Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol, 2006,290:C917-24.
[15]Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem, 2004,279:7370-7.
[16]Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood,2003,101:2652-60.
[17]Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med,2003,254:375-85.
[18]Park JS, Arcaroli J, Yum HK, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol, 2003,284:C870-9.
[19]Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1:an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol,2004,173:307-13.
[20]Agnello D, Wang H, Yang H, et al. HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine,2002,18:231-6.
[21]Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol,2000,165:2950-4.
[22]Taylor BE, Buchman TG. Is there a role for growth hormone therapy in refractory critical illness. Curr Opin Crit Care,2008,14:438-44.
[23]Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly:a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab,2010,95:567-77.
[24]Yi C, Cao Y, Mao SH, et al. Recombinant human growth hormone improves survival and protects against acute lung injury in murine Staphylococcus aureus sepsis. Inflamm Res,2009,58:855-62.
[25]Saadeh E, Ikizler TA, Shyr Y, et al. Recombinant human growth hormone in patients with acute renal failure. J Ren Nutr,2001,11:212-9.
[26]Wang X, Wang B, Wu K, et al. Growth hormone downregulated the excessive apoptosis of ileal intestinal epithelial cells in rats during the early course of acute necrotizing pancreatitis. Pancreas,2002,25:205-9.
[27]Scopa CD, Koureleas S, Tsamandas AC, et al. Beneficial effects of growth hormone and insulin-like growth factor I on intestinal bacterial translocation, endotoxemia, and apoptosis in experimentally jaundiced rats. J Am Coll Surg, 2000,190:423-31.
[28]Ashare A, Nymon AB, Doerschug KC, et al. Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance. Am J Respir Crit Care Med,2008,178:149-57.
[29]秦爽,贺育兰,杨静,等.重组人生长激素对内毒素诱导人巨噬细胞产生TNF-α、IL-1β含量的影响.中国感染控制杂志,2008,7：9-11.
[30]Ogiku M, Kono H, Ishii K, et al. Role of Macrophage Colony-Stimulating Factor in Polymicrobial Sepsis According to Studies Using Osteopetrotic (op/op) Mice. J Surg Res,2009.
[31]Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol,2007,81:137-43.
[32]Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg, 2007,245:480-6.
[33]Gogos CA, Drosou E, Bassaris HP, et al. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis:a marker for prognosis and future therapeutic options. J Infect Dis,2000,181:176-80.
[34]Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med, 1993,119:771-8.
[35]Dinarello CA. Proinflammatory cytokines. Chest,2000,118:503-8.
[36]Schwanzer-Pfeiffer D, Mitteregger R, Rossmanith E, et al. Comparison of specific adsorbents for tumor necrosis factor-alpha and therapeutic anti-tumor necrosis factor-alpha antibodies:an in vitro sepsis model. Int J Artif Organs, 2006,29:1140-7.
[37]Turnbull IR, Clark AT, Stromberg PE, et al. Effects of aging on the immunopathologic response to sepsis. Crit Care Med,2009,37:1018-23.
[38]Namath A, Patterson AJ. Genetic polymorphisms in sepsis. Crit Care Clin, 2009,25:835-56, x.
[39]Teuffel O, Ethier MC, Beyene J, et al. Association between tumor necrosis factor-alpha promoter-308 A/G polymorphism and susceptibility to sepsis and sepsis mortality:a systematic review and meta-analysis. Crit Care Med, 2010,38:276-82.
[40]Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care,2009,15:392-7.
[41]Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab,2007,293:E453-9.
[42]RABEN MS. Preparation of growth hormone from pituitaries of man and monkey. Science,1957,125:883-4.
[43]Kemp SF. Insulin-like growth factor-Ⅰ deficiency in children with growth hormone insensitivity:current and future treatment options. BioDrugs, 2009,23:155-63.
[44]Guo Y, Bai X, Lin G, et al. Altered nutrition state in the severe multiple trauma patients undergoing adjuvant recombinant human growth hormone nutritional support therapy. J Huazhong Univ Sci Technolog Med Sci,2007,27:299-302.
[45]Esposito E, Mazzon E, Muia C, et al. Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF-alpha. J Leukoc Biol,2007,81:1032-43.
[46]Yajima S, Morisaki H, Serita R, et al. Tumor necrosis factor-alpha mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia. Crit Care Med,2009,37:1024-30.
[47]Freise H, Daudel F, Grosserichter C, et al. Thoracic epidural anesthesia reverses sepsis-induced hepatic hyperperfusion and reduces leukocyte adhesion in septic rats. Crit Care,2009,13:R116.
[48]Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science,1999,285:248-51.
[49]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001,25:402-8.
[50]Kim JY, Lee SM. Effect of ascorbic acid on hepatic vasoregulatory gene expression during polymicrobial sepsis. Life Sci,2004,75:2015-26.
[51]Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med,2001,164:1768-73.
[52]Matsuda N, Hattori Y. Vascular biology in sepsis:pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res, 2007,43:117-37.
[53]Lee SH, Clemens MG, Lee SM. Role of Kupffer cells in vascular stress genes during trauma and sepsis. J Surg Res,2010,158:104-11.
[54]Grau T, Bonet A. Caloric intake and liver dysfunction in critically ill patients. Curr Opin Clin Nutr Metab Care,2009,12:175-9.
[55]Koo DJ, Chaudry IH, Wang P. Mechanism of hepatocellular dysfunction during sepsis:the role of gut-derived norepinephrine (review). Int J Mol Med, 2000,5:457-65.
[56]Zhang F, Wu R, Qiang X, et al. Antagonism of alpha2A-adrenoceptor:a novel approach to inhibit inflammatory responses in sepsis. J Mol Med, 2010,88:289-96.
[57]Fink MP. Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Crit Care Med,1991,19:627-41.
[58]Ersoy B, Ozbilgin K, Kasirga E, et al. Effect of growth hormone on small intestinal homeostasis relation to cellular mediators IGF-Ⅰ and IGFBP-3. World J Gastroenterol,2009,15:5418-24.
[59]Wang X, Wang B, Wu J, et al. Beneficial effects of growth hormone on bacterial translocation during the course of acute necrotizing pancreatitis in rats. Pancreas,2001,23:148-56.
[60]Stros M. HMGB proteins:interactions with DNA and chromatin. Biochim Biophys Acta,2010,1799:101-13.
[61]Bopp C, Bierhaus A, Hofer S, et al. Bench-to-bedside review:The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care,2008,12:201.
[62]Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett, 2010.192:387-94.
[63]Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med, 2005,201:1135-43.
[64]Hou LC, Qin MZ, Zheng LN, et al. Severity of sepsis is correlated with the elevation of serum high-mobility group box 1 in rats. Chin Med J (Engl), 2009,122:449-54.
[65]Yang R, Harada T, Mollen KP, et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med,2006,12:105-14.
[66]Sappington PL, Yang R, Yang H, et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology,2002,123:790-802.
[67]Zhao ZF, Han DW, Liu MS, et al. [Expression of HMGB-1 and its extracellular release of cultured primary hepatic parenchymal cells and Kupffer cells induced by LPS]. Zhonghua Gan Zang Bing Za Zhi, 2007,15:676-80.
[68]Chen HW, Kuo HT, Wang SJ, et al. In vivo heat shock protein assembles with septic liver NF-kappaB/I-kappaB complex regulating NF-kappaB activity. Shock,2005,24:232-8.
[69]Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol, 2006.290:L622-L645.
[70]Schmidt C, Hocherl K, Kurt B, et al. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine,2010,49:30-8.
[71]Xu H, Ye X, Steinberg H, et al. Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. J Pathol,2010,220:490-8.
[72]Ye X, Ding J, Zhou X, et al. Divergent roles of endothelial NF-kappaB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med,2008,205:1303-15.
[73]Yi C, Wang SR, Zhang SY, et al. Effects of recombinant human growth hormone on acute lung injury in endotoxemic rats. Inflamm Res, 2006,55:491-7.
[74]Wu R, Dong W, Zhou M, et al. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res,2005,68:318-26.
[75]Hou Y, An J, Hu XR, et al. Ghrelin inhibits interleukin-8 production induced by hydrogen peroxide in A549 cells via NF-kappaB pathway. Int Immunopharmacol,2009,9:120-6.
[76]Wesche-Soldato DE, Swan RZ, Chung CS, et al. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets,2007,8:493-500.
[77]Wesche-Soldato DE, Chung CS, Lomas-Neira J, et al. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood, 2005,106:2295-301.
[78]Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med,2006,203:1637-42.
[79]张大志,张定凤,等.重组人生长激素对内毒素致肝细胞凋亡效应的抑制作用.中华肝脏病杂志,2001,9：100-102.
[1]Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem, 1973,38:14-9.
[2]Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci,2001,26:152-3.
[3]Dumitriu IE, Baruah P, Manfredi AA, et al. HMGB1:guiding immunity from within. Trends Immunol,2005,26:381-7.
[4]Melvin VS, Roemer SC, Churchill ME, et al. The C-terminal extension (CTE) of the nuclear hormone receptor DNA binding domain determines interactions and functional response to the HMGB-1/-2 co-regulatory proteins. J Biol Chem,2002,277:25115-24.
[5]Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol,2005,78:1-8.
[6]Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol, 1999,19:5237-46.
[7]Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev, 2007,220:35-46.
[8]Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol,2007,8:487-96.
[9]Wang Q, Zeng M, Wang W, et al. The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism. Biochem Biophys Res Commun,2007,360:14-9.
[10]Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med,2004,255:332-43.
[11]Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med,2003,9:37-45.
[12]Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1:an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol,2004,173:307-13.
[13]Bustin M, Hopkins RB, Isenberg I. Immunological relatedness of high mobility group chromosomal proteins from calf thymus. J Biol Chem, 1978,253:1694-9.
[14]Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A, 2004,101:296-301.
[15]Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1):nuclear weapon in the immune arsenal. Nat Rev Immunol,2005,5:331-42.
[16]Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions:role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol, 2004,24:2320-5.
[17]Chen G, Li J, Ochani M, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD 14-and TNF-dependent mechanisms. J Leukoc Biol,2004,76:994-1001.
[18]Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J, 2003,22:5551-60.
[19]Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. Nat Med,2004,10:124-5.
[20]Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood, 2007,110:1970-81.
[21]Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature,2002,418:191-5.
[22]Pisetsky DS, Jiang W. Role of Toll-like receptors in HMGB1 release from macrophages. Ann N Y Acad Sci,2007,1109:58-65.
[23]Qin S, Wang H, Yuan R, et al. Role of HMGB 1 in apoptosis-mediated sepsis lethality. J Exp Med,2006,203:1637-42.
[24]Rouhiainen A, Imai S, Rauvala H, et al. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost,2000,84:1087-94.
[25]Huttunen HJ, Fages C, Kuja-Panula J, et al. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res,2002,62:4805-11.
[26]Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem, 1992,267:14987-97.
[27]Poirier O, Nicaud V, Vionnet N, et al. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes,2001,50:1214-8.
[28]Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem, 1992,267:14998-5004.
[29]Valencia JV, Mone M, Zhang J, et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes, 2004,53:743-51.
[30]Stern D, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev,2002,54:1615-25.
[31]Palumbo R, Galvez BG, Pusterla T, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol,2007,179:33-40.
[32]Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol,2005,174:7506-15.
[33]Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol,2007,81:59-66.
[34]Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J, 2007,26:1129-39.
[35]Telusma G, Datta S, Mihajlov I, et al. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol,2006,18:1563-73.
[36]Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem,1999,274:19919-24.
[37]Taguchi A, Blood DC, del TG, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature,2000,405:354-60.
[38]Zill H, Bek S, Hofmann T, et al. RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun, 2003,300:311-5.
[39]Huttunen HJ, Kuja-Panula J, Sorci G, et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem, 2000,275:40096-105.
[40]Murphy G, Gavrilovic J. Proteolysis and cell migration:creating a path. Curr Opin Cell Biol,1999,11:614-21.
[41]Andersson U, Erlandsson-Harris H, Yang H, et al. HMGB1 as a DNA-binding cytokine. J Leukoc Biol,2002,72:1084-91.
[42]Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol,2004,164:441-9.
[43]Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol, 2006,290:C917-24.
[44]Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med,2007,13:1050-9.
[45]Fages C, Nolo R, Huttunen HJ, et al. Regulation of cell migration by amphoterin. J Cell Sci,2000,113 (Pt 4):611-20.
[46]Choi YR, Kim H, Kang HJ, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res, 2003,63:2188-93.
[47]Zayed H, Izsvak Z, Khare D, et al. The DNA-bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res, 2003,31:2313-22.
[48]Muller S, Scaffidi P, Degryse B, et al. New EMBO members' review:the double life of HMGB1 chromatin protein:architectural factor and extracellular signal. EMBO J,2001,20:4337-40.
[49]Liu Y, Prasad R, Wilson SH. HMGB1:Roles in base excision repair and related function. Biochim Biophys Acta,2010,1799:119-30.
[50]Stros M, Bacikova A, Polanska E, et al. HMGB1 interacts with human topoisomerase Ilalpha and stimulates its catalytic activity. Nucleic Acids Res, 2007,35:5001-13.
[51]Catez F, Ueda T, Bustin M. Determinants of histone H1 mobility and chromatin binding in living cells. Nat Struct Mol Biol,2006,13:305-10.
[52]Stros M. HMGB proteins:Interactions with DNA and chromatin. Biochim Biophys Acta,2010,1799:101-113.
[53]Merenmies J, Pihlaskari R, Laitinen J, et al.30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem, 1991,266:16722-9.
[54]Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science,1999,285:248-51.
[55]Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med,2001,164:1768-73.
[56]Kocsis AK, Szabolcs A, Hofner P, et al. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology,2009,9:383-91.
[57]姚咏明.我国创伤脓毒症基础研究新进展.中华创伤杂志,2003：8-11.
[58]Sha Y, Zmijewski J, Xu Z, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol,2008,180:2531-7.
[59]Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol,2000,165:2950-4.
[60]Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock,2009,32:348-57.
[61]Sappington PL, Yang R, Yang H, et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology,2002,123:790-802.
[62]Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med,2000,192:565-70.
[63]Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis, 2003,35:577-84.
[64]Wang H, Yang H, Tracey KJ. Extracellular role of HMGB 1 in inflammation and sepsis. J Intern Med,2004,255:320-31.
[65]Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum,2003,48:971-81.
[66]Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1:a novel proinflammatory mediator in synovitis. Arthritis Rheum,2002,46:2598-603.
[67]Goldstein RS, Bruchfeld A, Yang L, et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med,2007,13:210-5.
[68]Pullerits R, Jonsson IM, Verdrengh M, et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum,2003,48:1693-700.
[69]Pullerits R, Brisslert M, Jonsson IM, et al. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum,2006,54:3898-907.
[70]Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum,2003,48:2052-8.
[71]Popovic K, Ek M, Espinosa A, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum, 2005,52:3639-45.
[72]Santoro P, De Andrea M, Migliaretti G, et al. High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases. J Rheumatol,2002,29:90-3.
[73]Fineschi S, Borghi MO, Riboldi P, et al. Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. Lupus,2004,13:463-8.
[74]Uesugi H, Ozaki S, Sobajima J, et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol, 1998,25:703-9.
[75]Ulfgren AK, Grundtman C, Borg K, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum, 2004,50:1586-94.
[76]Ayer LM, Senecal JL, Martin L, et al. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol,1994,21:2071-5.
[77]Ek M, Popovic K, Harris HE, et al. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum, 2006,54:2289-94.
[78]Taira T, Matsuyama W, Mitsuyama H, et al. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol, 2007,148:241-7.
[79]Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma:pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am, 2005,89:313-44, viii.
[80]Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol,2010.
[81]Shah KM, Young LS. Epstein-Barr virus and carcinogenesis:beyond Burkitt's lymphoma. Clin Microbiol Infect,2009,15:982-8.
[82]Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma:An update focusing on risk factors. Cancer Sci,2009.
[83]Poser I, Bosserhoff AK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol,2004,19:173-88.
[84]Bosserhoff AK, Hauschild A, Hein R, et al. Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas:results of a German multicenter study. J Invest Dermatol,2000,114:395-6.
[85]Poser I, Golob M, Buettner R, et al. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol,2003,23:2991-8.
[86]黄庆先,孙念峰,王国斌,等.高迁移率族蛋白1基因在胰腺癌组织中的表达及其临床意义.实用癌症杂志,2004,19：19-20,23.
[87]Takada M, Hirata K, Ajiki T, et al. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology,2004,51:928-30.
[88]Kuniyasu H, Chihara Y, Kondo H, et al. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep,2003,10:1863-8.
[89]Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate,2005,64:92-100.
[90]Brezniceanu ML, Volp K, Bosser S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J,2003,17:1295-7.
[91]Das D, Peterson RC, Scovell WM. High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol,2004,18:2616-32.
[92]Melvin VS, Harrell C, Adelman JS, et al. The role of the C-terminal extension (CTE) of the estrogen receptor alpha and beta DNA binding domain in DNA binding and interaction with HMGB. J Biol Chem,2004,279:14763-71.
[93]Flohr AM, Rogalla P, Meiboom M, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res,2001,21:3881-5.
[94]Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut, 2006,55:234-42.
[95]李焱,何建民,潘凤,等.结肠癌组织HMGB1和VEGF-D的表达及其相关性.临床肿瘤学杂志,2009,14：694-697.
[96]Sasahira T, Akama Y, Fujii K, et al. Expression of receptor for advanced glycation end products and HMGB 1/amphoterin in colorectal adenomas. Virchows Arch,2005,446:411-5.
[97]Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer, 2003,104:722-7.
[98]Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol,2002,196:163-70.
[99]Takeuchi A, Yamamoto Y, Tsuneyama K, et al. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer,2007,109:2532-40.
[100]Takada M, Koizumi T, Toyama H, et al. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology,2001,48:1577-8.
[101]McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol,2002,22:6797-808.
[102]Banerjee S, Kundu TK. The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res,2003,31:3236-47.
[103]Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res,2005,65:5009-14.
[104]van BJR, Dings RP, der Linden E v, et al. Gene expression of tumor angiogenesis dissected:specific targeting of colon cancer angiogenic vasculature. Blood,2006,108:2339-48.
[105]Sparatore B, Patrone M, Passalacqua M, et al. Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J,2005,389:215-21.
[106]van BJR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis,2008,11:91-9.
[107]Chavakis E, Hain A, Vinci M, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res, 2007,100:204-12.
[108]Kuniyasu H, Sasaki T, Sasahira T, et al. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology,2004,71:129-36.
[109]Kuniyasu H, Yano S, Sasaki T, et al. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol,2005,166:751-60.
[110]Zhang LT, Yao YM, Lu JQ, et al. Sodium butyrate prevents lethality of severe sepsis in rats. Shock,2007,27:672-7.
[111]Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA,2002,99:12351-6.
[112]Cai B, Deitch EA, Grande D, et al. Anti-inflammatory resuscitation improves survival in hemorrhage with trauma. J Trauma,2009,66:1632-9; discussion 1639-40.
[2]Schlichting D, McCollam JS. Recognizing and managing severe sepsis:a common and deadly threat. South Med J,2007,100:594-600.
[3]Toussaint S, Gerlach H. Activated protein C for sepsis. N Engl J Med, 2009,361:2646-52.
[4]Kim JH, Kim SJ, Lee IS, et al. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol, 2009,182:2458-66.
[5]Koskinas J, Gomatos IP, Tiniakos DG, et al. Liver histology in ICU patients dying from sepsis:a clinico-pathological study. World J Gastroenterol, 2008,14:1389-93.
[6]Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med,2004,255:332-43.
[7]Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med,2003,9:37-45.
[8]Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol,2005,78:1-8.
[9]Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature,2002,418:191-5.
[10]Sha Y, Zmijewski J, Xu Z, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol,2008,180:2531-7.
[11]Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1):nuclear weapon in the immune arsenal. Nat Rev Immunol,2005,5:331-42.
[12]Stern D, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev,2002,54:1615-25.
[13]Mishra PR, Jain NK. Surface modified methotrexate loaded erythrocytes for enhanced macrophage uptake. J Drug Target,2000,8:217-24.
[14]Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol, 2006,290:C917-24.
[15]Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem, 2004,279:7370-7.
[16]Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood,2003,101:2652-60.
[17]Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med,2003,254:375-85.
[18]Park JS, Arcaroli J, Yum HK, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol, 2003,284:C870-9.
[19]Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1:an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol,2004,173:307-13.
[20]Agnello D, Wang H, Yang H, et al. HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine,2002,18:231-6.
[21]Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol,2000,165:2950-4.
[22]Taylor BE, Buchman TG. Is there a role for growth hormone therapy in refractory critical illness. Curr Opin Crit Care,2008,14:438-44.
[23]Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly:a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab,2010,95:567-77.
[24]Yi C, Cao Y, Mao SH, et al. Recombinant human growth hormone improves survival and protects against acute lung injury in murine Staphylococcus aureus sepsis. Inflamm Res,2009,58:855-62.
[25]Saadeh E, Ikizler TA, Shyr Y, et al. Recombinant human growth hormone in patients with acute renal failure. J Ren Nutr,2001,11:212-9.
[26]Wang X, Wang B, Wu K, et al. Growth hormone downregulated the excessive apoptosis of ileal intestinal epithelial cells in rats during the early course of acute necrotizing pancreatitis. Pancreas,2002,25:205-9.
[27]Scopa CD, Koureleas S, Tsamandas AC, et al. Beneficial effects of growth hormone and insulin-like growth factor I on intestinal bacterial translocation, endotoxemia, and apoptosis in experimentally jaundiced rats. J Am Coll Surg, 2000,190:423-31.
[28]Ashare A, Nymon AB, Doerschug KC, et al. Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance. Am J Respir Crit Care Med,2008,178:149-57.
[29]秦爽,贺育兰,杨静,等.重组人生长激素对内毒素诱导人巨噬细胞产生TNF-α、IL-1β含量的影响.中国感染控制杂志,2008,7：9-11.
[30]Ogiku M, Kono H, Ishii K, et al. Role of Macrophage Colony-Stimulating Factor in Polymicrobial Sepsis According to Studies Using Osteopetrotic (op/op) Mice. J Surg Res,2009.
[31]Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol,2007,81:137-43.
[32]Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg, 2007,245:480-6.
[33]Gogos CA, Drosou E, Bassaris HP, et al. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis:a marker for prognosis and future therapeutic options. J Infect Dis,2000,181:176-80.
[34]Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med, 1993,119:771-8.
[35]Dinarello CA. Proinflammatory cytokines. Chest,2000,118:503-8.
[36]Schwanzer-Pfeiffer D, Mitteregger R, Rossmanith E, et al. Comparison of specific adsorbents for tumor necrosis factor-alpha and therapeutic anti-tumor necrosis factor-alpha antibodies:an in vitro sepsis model. Int J Artif Organs, 2006,29:1140-7.
[37]Turnbull IR, Clark AT, Stromberg PE, et al. Effects of aging on the immunopathologic response to sepsis. Crit Care Med,2009,37:1018-23.
[38]Namath A, Patterson AJ. Genetic polymorphisms in sepsis. Crit Care Clin, 2009,25:835-56, x.
[39]Teuffel O, Ethier MC, Beyene J, et al. Association between tumor necrosis factor-alpha promoter-308 A/G polymorphism and susceptibility to sepsis and sepsis mortality:a systematic review and meta-analysis. Crit Care Med, 2010,38:276-82.
[40]Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care,2009,15:392-7.
[41]Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab,2007,293:E453-9.
[42]RABEN MS. Preparation of growth hormone from pituitaries of man and monkey. Science,1957,125:883-4.
[43]Kemp SF. Insulin-like growth factor-Ⅰ deficiency in children with growth hormone insensitivity:current and future treatment options. BioDrugs, 2009,23:155-63.
[44]Guo Y, Bai X, Lin G, et al. Altered nutrition state in the severe multiple trauma patients undergoing adjuvant recombinant human growth hormone nutritional support therapy. J Huazhong Univ Sci Technolog Med Sci,2007,27:299-302.
[45]Esposito E, Mazzon E, Muia C, et al. Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF-alpha. J Leukoc Biol,2007,81:1032-43.
[46]Yajima S, Morisaki H, Serita R, et al. Tumor necrosis factor-alpha mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia. Crit Care Med,2009,37:1024-30.
[47]Freise H, Daudel F, Grosserichter C, et al. Thoracic epidural anesthesia reverses sepsis-induced hepatic hyperperfusion and reduces leukocyte adhesion in septic rats. Crit Care,2009,13:R116.
[48]Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science,1999,285:248-51.
[49]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001,25:402-8.
[50]Kim JY, Lee SM. Effect of ascorbic acid on hepatic vasoregulatory gene expression during polymicrobial sepsis. Life Sci,2004,75:2015-26.
[51]Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med,2001,164:1768-73.
[52]Matsuda N, Hattori Y. Vascular biology in sepsis:pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res, 2007,43:117-37.
[53]Lee SH, Clemens MG, Lee SM. Role of Kupffer cells in vascular stress genes during trauma and sepsis. J Surg Res,2010,158:104-11.
[54]Grau T, Bonet A. Caloric intake and liver dysfunction in critically ill patients. Curr Opin Clin Nutr Metab Care,2009,12:175-9.
[55]Koo DJ, Chaudry IH, Wang P. Mechanism of hepatocellular dysfunction during sepsis:the role of gut-derived norepinephrine (review). Int J Mol Med, 2000,5:457-65.
[56]Zhang F, Wu R, Qiang X, et al. Antagonism of alpha2A-adrenoceptor:a novel approach to inhibit inflammatory responses in sepsis. J Mol Med, 2010,88:289-96.
[57]Fink MP. Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Crit Care Med,1991,19:627-41.
[58]Ersoy B, Ozbilgin K, Kasirga E, et al. Effect of growth hormone on small intestinal homeostasis relation to cellular mediators IGF-Ⅰ and IGFBP-3. World J Gastroenterol,2009,15:5418-24.
[59]Wang X, Wang B, Wu J, et al. Beneficial effects of growth hormone on bacterial translocation during the course of acute necrotizing pancreatitis in rats. Pancreas,2001,23:148-56.
[60]Stros M. HMGB proteins:interactions with DNA and chromatin. Biochim Biophys Acta,2010,1799:101-13.
[61]Bopp C, Bierhaus A, Hofer S, et al. Bench-to-bedside review:The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care,2008,12:201.
[62]Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett, 2010.192:387-94.
[63]Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med, 2005,201:1135-43.
[64]Hou LC, Qin MZ, Zheng LN, et al. Severity of sepsis is correlated with the elevation of serum high-mobility group box 1 in rats. Chin Med J (Engl), 2009,122:449-54.
[65]Yang R, Harada T, Mollen KP, et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med,2006,12:105-14.
[66]Sappington PL, Yang R, Yang H, et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology,2002,123:790-802.
[67]Zhao ZF, Han DW, Liu MS, et al. [Expression of HMGB-1 and its extracellular release of cultured primary hepatic parenchymal cells and Kupffer cells induced by LPS]. Zhonghua Gan Zang Bing Za Zhi, 2007,15:676-80.
[68]Chen HW, Kuo HT, Wang SJ, et al. In vivo heat shock protein assembles with septic liver NF-kappaB/I-kappaB complex regulating NF-kappaB activity. Shock,2005,24:232-8.
[69]Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol, 2006.290:L622-L645.
[70]Schmidt C, Hocherl K, Kurt B, et al. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine,2010,49:30-8.
[71]Xu H, Ye X, Steinberg H, et al. Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. J Pathol,2010,220:490-8.
[72]Ye X, Ding J, Zhou X, et al. Divergent roles of endothelial NF-kappaB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med,2008,205:1303-15.
[73]Yi C, Wang SR, Zhang SY, et al. Effects of recombinant human growth hormone on acute lung injury in endotoxemic rats. Inflamm Res, 2006,55:491-7.
[74]Wu R, Dong W, Zhou M, et al. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res,2005,68:318-26.
[75]Hou Y, An J, Hu XR, et al. Ghrelin inhibits interleukin-8 production induced by hydrogen peroxide in A549 cells via NF-kappaB pathway. Int Immunopharmacol,2009,9:120-6.
[76]Wesche-Soldato DE, Swan RZ, Chung CS, et al. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets,2007,8:493-500.
[77]Wesche-Soldato DE, Chung CS, Lomas-Neira J, et al. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood, 2005,106:2295-301.
[78]Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med,2006,203:1637-42.
[79]张大志,张定凤,等.重组人生长激素对内毒素致肝细胞凋亡效应的抑制作用.中华肝脏病杂志,2001,9：100-102.
[1]Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem, 1973,38:14-9.
[2]Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci,2001,26:152-3.
[3]Dumitriu IE, Baruah P, Manfredi AA, et al. HMGB1:guiding immunity from within. Trends Immunol,2005,26:381-7.
[4]Melvin VS, Roemer SC, Churchill ME, et al. The C-terminal extension (CTE) of the nuclear hormone receptor DNA binding domain determines interactions and functional response to the HMGB-1/-2 co-regulatory proteins. J Biol Chem,2002,277:25115-24.
[5]Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol,2005,78:1-8.
[6]Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol, 1999,19:5237-46.
[7]Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev, 2007,220:35-46.
[8]Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol,2007,8:487-96.
[9]Wang Q, Zeng M, Wang W, et al. The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism. Biochem Biophys Res Commun,2007,360:14-9.
[10]Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med,2004,255:332-43.
[11]Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med,2003,9:37-45.
[12]Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1:an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol,2004,173:307-13.
[13]Bustin M, Hopkins RB, Isenberg I. Immunological relatedness of high mobility group chromosomal proteins from calf thymus. J Biol Chem, 1978,253:1694-9.
[14]Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A, 2004,101:296-301.
[15]Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1):nuclear weapon in the immune arsenal. Nat Rev Immunol,2005,5:331-42.
[16]Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions:role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol, 2004,24:2320-5.
[17]Chen G, Li J, Ochani M, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD 14-and TNF-dependent mechanisms. J Leukoc Biol,2004,76:994-1001.
[18]Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J, 2003,22:5551-60.
[19]Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. Nat Med,2004,10:124-5.
[20]Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood, 2007,110:1970-81.
[21]Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature,2002,418:191-5.
[22]Pisetsky DS, Jiang W. Role of Toll-like receptors in HMGB1 release from macrophages. Ann N Y Acad Sci,2007,1109:58-65.
[23]Qin S, Wang H, Yuan R, et al. Role of HMGB 1 in apoptosis-mediated sepsis lethality. J Exp Med,2006,203:1637-42.
[24]Rouhiainen A, Imai S, Rauvala H, et al. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost,2000,84:1087-94.
[25]Huttunen HJ, Fages C, Kuja-Panula J, et al. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res,2002,62:4805-11.
[26]Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem, 1992,267:14987-97.
[27]Poirier O, Nicaud V, Vionnet N, et al. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes,2001,50:1214-8.
[28]Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem, 1992,267:14998-5004.
[29]Valencia JV, Mone M, Zhang J, et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes, 2004,53:743-51.
[30]Stern D, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev,2002,54:1615-25.
[31]Palumbo R, Galvez BG, Pusterla T, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol,2007,179:33-40.
[32]Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol,2005,174:7506-15.
[33]Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol,2007,81:59-66.
[34]Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J, 2007,26:1129-39.
[35]Telusma G, Datta S, Mihajlov I, et al. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol,2006,18:1563-73.
[36]Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem,1999,274:19919-24.
[37]Taguchi A, Blood DC, del TG, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature,2000,405:354-60.
[38]Zill H, Bek S, Hofmann T, et al. RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun, 2003,300:311-5.
[39]Huttunen HJ, Kuja-Panula J, Sorci G, et al. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem, 2000,275:40096-105.
[40]Murphy G, Gavrilovic J. Proteolysis and cell migration:creating a path. Curr Opin Cell Biol,1999,11:614-21.
[41]Andersson U, Erlandsson-Harris H, Yang H, et al. HMGB1 as a DNA-binding cytokine. J Leukoc Biol,2002,72:1084-91.
[42]Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol,2004,164:441-9.
[43]Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol, 2006,290:C917-24.
[44]Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med,2007,13:1050-9.
[45]Fages C, Nolo R, Huttunen HJ, et al. Regulation of cell migration by amphoterin. J Cell Sci,2000,113 (Pt 4):611-20.
[46]Choi YR, Kim H, Kang HJ, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res, 2003,63:2188-93.
[47]Zayed H, Izsvak Z, Khare D, et al. The DNA-bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res, 2003,31:2313-22.
[48]Muller S, Scaffidi P, Degryse B, et al. New EMBO members' review:the double life of HMGB1 chromatin protein:architectural factor and extracellular signal. EMBO J,2001,20:4337-40.
[49]Liu Y, Prasad R, Wilson SH. HMGB1:Roles in base excision repair and related function. Biochim Biophys Acta,2010,1799:119-30.
[50]Stros M, Bacikova A, Polanska E, et al. HMGB1 interacts with human topoisomerase Ilalpha and stimulates its catalytic activity. Nucleic Acids Res, 2007,35:5001-13.
[51]Catez F, Ueda T, Bustin M. Determinants of histone H1 mobility and chromatin binding in living cells. Nat Struct Mol Biol,2006,13:305-10.
[52]Stros M. HMGB proteins:Interactions with DNA and chromatin. Biochim Biophys Acta,2010,1799:101-113.
[53]Merenmies J, Pihlaskari R, Laitinen J, et al.30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem, 1991,266:16722-9.
[54]Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science,1999,285:248-51.
[55]Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med,2001,164:1768-73.
[56]Kocsis AK, Szabolcs A, Hofner P, et al. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology,2009,9:383-91.
[57]姚咏明.我国创伤脓毒症基础研究新进展.中华创伤杂志,2003：8-11.
[58]Sha Y, Zmijewski J, Xu Z, et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol,2008,180:2531-7.
[59]Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol,2000,165:2950-4.
[60]Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock,2009,32:348-57.
[61]Sappington PL, Yang R, Yang H, et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology,2002,123:790-802.
[62]Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med,2000,192:565-70.
[63]Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis, 2003,35:577-84.
[64]Wang H, Yang H, Tracey KJ. Extracellular role of HMGB 1 in inflammation and sepsis. J Intern Med,2004,255:320-31.
[65]Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum,2003,48:971-81.
[66]Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1:a novel proinflammatory mediator in synovitis. Arthritis Rheum,2002,46:2598-603.
[67]Goldstein RS, Bruchfeld A, Yang L, et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med,2007,13:210-5.
[68]Pullerits R, Jonsson IM, Verdrengh M, et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum,2003,48:1693-700.
[69]Pullerits R, Brisslert M, Jonsson IM, et al. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum,2006,54:3898-907.
[70]Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum,2003,48:2052-8.
[71]Popovic K, Ek M, Espinosa A, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum, 2005,52:3639-45.
[72]Santoro P, De Andrea M, Migliaretti G, et al. High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases. J Rheumatol,2002,29:90-3.
[73]Fineschi S, Borghi MO, Riboldi P, et al. Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. Lupus,2004,13:463-8.
[74]Uesugi H, Ozaki S, Sobajima J, et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol, 1998,25:703-9.
[75]Ulfgren AK, Grundtman C, Borg K, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum, 2004,50:1586-94.
[76]Ayer LM, Senecal JL, Martin L, et al. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol,1994,21:2071-5.
[77]Ek M, Popovic K, Harris HE, et al. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum, 2006,54:2289-94.
[78]Taira T, Matsuyama W, Mitsuyama H, et al. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol, 2007,148:241-7.
[79]Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma:pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am, 2005,89:313-44, viii.
[80]Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol,2010.
[81]Shah KM, Young LS. Epstein-Barr virus and carcinogenesis:beyond Burkitt's lymphoma. Clin Microbiol Infect,2009,15:982-8.
[82]Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma:An update focusing on risk factors. Cancer Sci,2009.
[83]Poser I, Bosserhoff AK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol,2004,19:173-88.
[84]Bosserhoff AK, Hauschild A, Hein R, et al. Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas:results of a German multicenter study. J Invest Dermatol,2000,114:395-6.
[85]Poser I, Golob M, Buettner R, et al. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol,2003,23:2991-8.
[86]黄庆先,孙念峰,王国斌,等.高迁移率族蛋白1基因在胰腺癌组织中的表达及其临床意义.实用癌症杂志,2004,19：19-20,23.
[87]Takada M, Hirata K, Ajiki T, et al. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology,2004,51:928-30.
[88]Kuniyasu H, Chihara Y, Kondo H, et al. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep,2003,10:1863-8.
[89]Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate,2005,64:92-100.
[90]Brezniceanu ML, Volp K, Bosser S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J,2003,17:1295-7.
[91]Das D, Peterson RC, Scovell WM. High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol,2004,18:2616-32.
[92]Melvin VS, Harrell C, Adelman JS, et al. The role of the C-terminal extension (CTE) of the estrogen receptor alpha and beta DNA binding domain in DNA binding and interaction with HMGB. J Biol Chem,2004,279:14763-71.
[93]Flohr AM, Rogalla P, Meiboom M, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res,2001,21:3881-5.
[94]Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut, 2006,55:234-42.
[95]李焱,何建民,潘凤,等.结肠癌组织HMGB1和VEGF-D的表达及其相关性.临床肿瘤学杂志,2009,14：694-697.
[96]Sasahira T, Akama Y, Fujii K, et al. Expression of receptor for advanced glycation end products and HMGB 1/amphoterin in colorectal adenomas. Virchows Arch,2005,446:411-5.
[97]Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer, 2003,104:722-7.
[98]Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol,2002,196:163-70.
[99]Takeuchi A, Yamamoto Y, Tsuneyama K, et al. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer,2007,109:2532-40.
[100]Takada M, Koizumi T, Toyama H, et al. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology,2001,48:1577-8.
[101]McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol,2002,22:6797-808.
[102]Banerjee S, Kundu TK. The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res,2003,31:3236-47.
[103]Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res,2005,65:5009-14.
[104]van BJR, Dings RP, der Linden E v, et al. Gene expression of tumor angiogenesis dissected:specific targeting of colon cancer angiogenic vasculature. Blood,2006,108:2339-48.
[105]Sparatore B, Patrone M, Passalacqua M, et al. Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J,2005,389:215-21.
[106]van BJR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis,2008,11:91-9.
[107]Chavakis E, Hain A, Vinci M, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res, 2007,100:204-12.
[108]Kuniyasu H, Sasaki T, Sasahira T, et al. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology,2004,71:129-36.
[109]Kuniyasu H, Yano S, Sasaki T, et al. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol,2005,166:751-60.
[110]Zhang LT, Yao YM, Lu JQ, et al. Sodium butyrate prevents lethality of severe sepsis in rats. Shock,2007,27:672-7.
[111]Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA,2002,99:12351-6.
[112]Cai B, Deitch EA, Grande D, et al. Anti-inflammatory resuscitation improves survival in hemorrhage with trauma. J Trauma,2009,66:1632-9; discussion 1639-40.